

## Effect of volatile anaesthetics on the calcium release channel in the heart

D.R. Laver, T. Quail, H. Sitsapesan and D.F. van Helden, School of Biomedical Sciences, University of Newcastle and Hunter Medical Research Institute, Callaghan, NSW 2308, Australia.

Although volatile anaesthetics serve a crucial role in preventing pain they continue to have a number of serious side effects. One of these is their ability to excite  $\text{Ca}^{2+}$  release from the intracellular  $\text{Ca}^{2+}$  stores (sarcoplasmic reticulum, SR) via calcium release channels named ryanodine receptors (RyR). This can result in fatal episodes of malignant hyperthermia in otherwise normal patients harbouring mutations in the skeletal muscle RyR isoform (RyR1, MacLennan & Chen, 1993). The cardiac isoform of the RyR (RyR2) plays a key role in cardiac muscle contraction, pacemaking and rhythmicity (Vinogradova *et al.*, 2005). During periods of ischemia, changes in the intracellular milieu cause a decrease in RyR activity and consequently an increase in SR  $\text{Ca}^{2+}$  load. Upon reperfusion of the heart tissue, recovery of RyR2 activity in the presence of abnormally high store loads leads to cardiac arrhythmias. Evidence now indicates that activation of RyR2 by volatile anaesthetics protects against myocardial injury and arrhythmias following ischemia and reperfusion (Yang *et al.*, 2005). Here we report the first detailed investigation on the effects of volatile anaesthetics on the function of cardiac RyRs.

RyRs were isolated from sheep hearts and incorporated into artificial lipid bilayers that separated baths corresponding to the cytoplasm and SR lumen. The activity of RyRs was measured using single channel recording. Volatile anaesthetics were added to the baths by injection of solutions from sealed reservoirs. These solutions contained the desired concentration of anaesthetic (either halothane or isoflurane) and were carefully titrated for various levels of free  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ . We found that clinical doses of these anaesthetics increased RyR2 open probability ( $P_o$ ) via increases in the channel mean open time and opening frequency. The  $K_a$ s for halothane and isoflurane were 1 mmol/l and 3 mmol/l, respectively. However, the maximal effect of halothane (5-fold increase in  $P_o$ ) was ~3-fold larger than that for isoflurane. These agents were shown to activate RyRs by interacting with their cytoplasmic domains. Furthermore, anaesthetic site of action was found to be distinct from the adenine nucleotide activating sites, contrary to previous suggestions (Yang *et al.*, 2005).

The effects of halothane on RyR2 regulation by cytoplasmic and luminal  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  were accurately fitted by a model based on a tetrameric RyR structure with four  $\text{Ca}^{2+}$  sensing mechanisms on each subunit (Laver, 2007; Laver & Honen, 2008); two activation sites (the luminal L-site with 40  $\mu\text{mol/l}$  affinity and the cytoplasmic A-site with 1  $\mu\text{mol/l}$  affinity) and two cytoplasmic inactivation sites ( $I_1$ -site with 10 mmol/l affinity and the  $I_2$ -site with 1  $\mu\text{mol/l}$  affinity). Halothane did not appear to alter the ion binding affinities for these sites. Rather, it increased channel opening rate and decreased the channel closing rate associated with  $\text{Ca}^{2+}$  binding to the two activation sites.

Laver DR.(2007) *Biophysical Journal*, **92**: 3541-55.

Laver DR & Honen BN. (2008) *Journal of General Physiology*, **in press**.

MacLennan DH & Chen SR. (1993) *Annals of the New York Academy of Science*, **707**: 294-304.

Vinogradova TM, Maltsev VA, Bogdanov KY, Lyashkov AE & Lakatta EG. (2005) *Annals of the New York Academy of Science*, **1047**: 138-56.

Yang Z, Harrison SM & Steele DS. (2005) *Cardiovascular Research*, **65**: 167-76.